The comparative effects of ω-7 fatty acid-rich sea buckthorn oil and ω-3 fatty acid-rich DHA algal oil on improving high-fat diet-induced hyperlipidemia.

This study explores the therapeutic potential of ω-3 algal oil (rich in DHA) and ω-7 sea buckthorn oil (rich in palmitoleic acid) in addressing hyperlipidemia and associated metabolic disorders. These oils regulate lipid metabolism through the PPARγ-LXRα-ABCA1/ABCG1 signaling pathway, reducing cholesterol accumulation, oxidative stress, and inflammation. In high-fat diet-induced hyperlipidemic mice, supplementation with these oils significantly improved lipid profiles, alleviated hepatic steatosis, and promoted cardiovascular health.

Protective Mechanism of Proanthocyanidins Against Hydrogen Peroxide-Introduced Oxidative Damage in Adult Retinal Pigment Epithelial-19.

Retinal pigment epithelial (RPE) is an oxidation-resistant cell. But if it is subjected to various harmful stimuli for a prolonged period, an excessive amount of oxyradical will be generated to cause retinal dysfunction. We investigated and elucidated the protective mechanism of proanthocyanidins (SBP) against oxidative damage in RPE.

Advances in understanding and management of IgG4-related ophthalmic disease.

Immunoglobulin G4-related ophthalmic disease (IgG4-ROD) is an emerging, immune-mediated fibroinflammatory orbital disease, characterized by tumefactive lesions with noticeable IgG4+ plasma cell infiltration and distinctive pathohistological features. This disease is often associated with elevated serum IgG4 concentrations. IgG4-ROD may affect any ophthalmic tissues, particularly the lacrimal gland, extraocular muscles, and trigeminal nerves.

Development and temporal validation of a clinical prediction model of transition to psychosis in individuals at ultra-high risk in the UHR 1000+ cohort.

The concept of ultra-high risk for psychosis (UHR) has been at the forefront of psychiatric research for several decades, with the ultimate goal of preventing the onset of psychotic disorder in high-risk individuals. Orygen (Melbourne, Australia) has led a range of observational and intervention studies in this clinical population. These datasets have now been integrated into the UHR 1000+ cohort, consisting of a sample of 1,245 UHR individuals with a follow-up period ranging from 1 to 16.